Navidea Biopharmaceutics Stock
Your prediction
Pros and Cons of Navidea Biopharmaceutics in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Navidea Biopharmaceutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Navidea Biopharmaceutics | - | - | - | - | - | - | - |
Chromadex Corp | 3.150% | -16.447% | -21.118% | 92.424% | 89.552% | -60.620% | - |
Organovo Holdings Inc. | -4.020% | -3.340% | -1.489% | -48.384% | -9.747% | -87.982% | -90.170% |
Intellia Therapeutics Inc | -3.920% | -11.660% | 7.867% | -42.444% | -27.772% | -65.978% | 62.724% |
News
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the